XML 110 R95.htm IDEA: XBRL DOCUMENT v3.22.4
LICENSE AND COLLABORATION AGREEMENTS (Details)
$ in Thousands, € in Millions
1 Months Ended 12 Months Ended
Oct. 31, 2019
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
[1]
Dec. 31, 2022
EUR (€)
Mar. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue | $   $ 2,096,039   $ 1,846,275 $ 1,860,455    
Firdapse | Disposal Group, Disposed of by Sale, Not Discontinued Operations              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Royalties on net product sales             7.00%
Royalties on net product sales             10.00%
Exclusive Licensing Agreement For Tralesinidase Alfa              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue | $ $ 3,000            
Investment in equity | $   $ 12,600          
Exclusive Licensing Agreement For Tralesinidase Alfa | Variable Interest Entity, Not Primary Beneficiary              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Minority equity ownership 15.00%            
A&R Kuvan Agreement | Merck Serono              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Contingent consideration | €           € 15.0  
A&R Kuvan Agreement | Merck Serono | Maximum              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Business acquisition contingent consideration potential cash payments upon achievement of sales milestone | €           € 60.0  
Pegvaliase Agreement | Merck Serono              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Business acquisition, cash paid | €     € 125.0        
[1] Certain December 31, 2020 amounts have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Consolidated Financial Statements for details.